Prnewswire·2025-10-30 16:00Core Insights - ChemDiv announced an extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration to support the clinical development of ratutrelvir, an oral antiviral treatment for COVID-19, following Traws Pharma's initiation of Phase 2 studies [1][3] - Ratutrelvir is a ritonavir-free Main protease inhibitor, designed to offer high potency against various SARS-CoV-2 strains, with a simplified 10-day treatment regimen [2][4] - The ongoing collaboration between ChemDiv, Traws Pharma, and Expert Systems aims to enhance the clinical development of ratutrelvir through advanced predictive safety pharmacology [3][5] Company Overview - ChemDiv is a global provider of integrated drug discovery solutions, offering a wide range of services including medicinal chemistry, CMC, and AI-powered drug design [9] - Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel antiviral therapies for respiratory viral diseases, including ratutrelvir for COVID-19 [8] - Expert Systems is an advanced AI-based platform that supports drug discovery and development, contributing to the predictive pharmacology of ratutrelvir [5] Clinical Development - Ratutrelvir is currently being evaluated in two Phase 2 studies: one comparing it to PAXLOVID® in newly diagnosed patients and another for PAXLOVID®-ineligible patients [3][4] - Phase 1 studies indicated that ratutrelvir maintained plasma levels approximately 13 times above the effective concentration with a once-daily dosing regimen, potentially reducing the risk of viral rebound and Long COVID [3]